Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors

NCT00931931 is registered in ClinicalTrials.gov with Timothy Cripe as lead sponsor.

NCT NCT00931931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00931931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors
Lead sponsor
Timothy Cripe
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2010
Completion date
March 19, 2018
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clival chordoma, ewing sarcoma, malignant peripheral nerve sheath tumor, neuroblastoma, non-cns solid tumors, osteosarcoma, rhabdomyosarcoma, soft tissue sarcoma, wilms tumor